Our data strongly support further preclinical and clinical evaluation of SSTR2-directed PRRT in liver cancer, particularly for tumors that demonstrate high SSTR2 expression and co-expression of actionable oncogenic targets. This evidence concerns the gene SSTR2 and liver cancer.